KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Q3 2025 value amounting to $49.5 million.

  • Aurinia Pharmaceuticals' Accumulated Expenses changed N/A to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year change of. This contributed to the annual value of $65.0 million for FY2024, which is 2978.11% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Accumulated Expenses stood at $49.5 million.
  • Over the past 5 years, Aurinia Pharmaceuticals' Accumulated Expenses peaked at $65.0 million during Q4 2024, and registered a low of $42.4 million during Q1 2025.
  • Its 3-year average for Accumulated Expenses is $51.3 million, with a median of $49.7 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' Accumulated Expenses was 2978.11% (2024), while the steepest drop was 2978.11% (2024).
  • Over the past 3 years, Aurinia Pharmaceuticals' Accumulated Expenses (Quarter) stood at $50.1 million in 2023, then grew by 29.78% to $65.0 million in 2024, then dropped by 23.76% to $49.5 million in 2025.
  • Its last three reported values are $49.5 million in Q3 2025, $49.7 million for Q2 2025, and $42.4 million during Q1 2025.